Currently 0 9 0 9 O
using 10 15 10 15 O
concomitant 16 27 16 27 O
medications 28 39 28 39 O
that 40 44 40 44 O
are 45 48 45 48 O
strong 49 55 49 55 O
inhibitors 56 66 56 66 O
or 67 69 67 69 O
inducers 70 78 70 78 O
of 79 81 79 81 O
CYP3A4 82 88 82 88 B-treatment

Have 0 4 89 93 O
a 5 6 94 95 O
performance 7 18 96 107 O
status 19 25 108 114 O
of 26 28 115 117 O
0 29 30 118 119 B-lower_bound
to 31 33 120 122 O
1 34 35 123 124 B-upper_bound
on 36 38 125 127 O
the 39 42 128 131 O
Eastern 43 50 132 139 B-clinical_variable
Cooperative 51 62 140 151 I-clinical_variable
Oncology 63 71 152 160 I-clinical_variable
Group 72 77 161 166 I-clinical_variable
( 78 79 167 168 I-clinical_variable
ECOG 79 83 168 172 I-clinical_variable
) 83 84 172 173 I-clinical_variable
scale 85 90 174 179 I-clinical_variable

Have 0 4 180 184 O
a 5 6 185 186 O
second 7 13 187 193 B-cancer
primary 14 21 194 201 I-cancer
malignancy 22 32 202 212 I-cancer
that 33 37 213 217 O
in 38 40 218 220 O
the 41 44 221 224 O
judgment 45 53 225 233 O
of 54 56 234 236 O
the 57 60 237 240 O
investigator 61 73 241 253 O
or 74 76 254 256 O
Lilly 77 82 257 262 O
may 83 86 263 266 O
affect 87 93 267 273 O
the 94 97 274 277 O
interpretation 98 112 278 292 O
of 113 115 293 295 O
results 116 123 296 303 O

Have 0 4 304 308 O
current 5 12 309 316 O
hematologic 13 24 317 328 B-cancer
malignancies 25 37 329 341 I-cancer
, 37 38 341 342 O
acute 39 44 343 348 B-cancer
or 45 47 349 351 I-cancer
chronic 48 55 352 359 I-cancer
leukemia 56 64 360 368 I-cancer

Have 0 4 369 373 O
history 5 12 374 381 O
or 13 15 382 384 O
findings 16 24 385 393 O
of 25 27 394 396 O
central 28 35 397 404 O
or 36 38 405 407 O
branch 39 45 408 414 O
retinal 46 53 415 422 O
artery 54 60 423 429 O
or 61 63 430 432 O
venous 64 70 433 439 O
occlusion 71 80 440 449 O
with 81 85 450 454 O
significant 86 97 455 466 O
vision 98 104 467 473 O
loss 105 109 474 478 O
or 110 112 479 481 O
other 113 118 482 487 O
retinal 119 126 488 495 B-chronic_disease
diseases 127 135 496 504 I-chronic_disease
that 136 140 505 509 O
cause 141 146 510 515 O
current 147 154 516 523 O
visual 155 161 524 530 O
impairment 162 172 531 541 O
or 173 175 542 544 O
would 176 181 545 550 O
likely 182 188 551 557 O
cause 189 194 558 563 O
visual 195 201 564 570 O
impairment 202 212 571 581 O
over 213 217 582 586 O
the 218 221 587 590 O
time 222 226 591 595 O
period 227 233 596 602 O
of 234 236 603 605 O
the 237 240 606 609 O
study 241 246 610 615 O

Have 0 4 616 620 O
participated 5 17 621 633 O
, 17 18 633 634 O
within 19 25 635 641 O
the 26 29 642 645 O
last 30 34 646 650 B-upper_bound
28 35 37 651 653 I-upper_bound
days 38 42 654 658 I-upper_bound
in 43 45 659 661 O
a 46 47 662 663 O
clinical 48 56 664 672 O
trial 57 62 673 678 O
involving 63 72 679 688 O
an 73 75 689 691 O
investigational 76 91 692 707 O
product 92 99 708 715 O
or 100 102 716 718 O
are 103 106 719 722 O
currently 107 116 723 732 O
enrolled 117 125 733 741 O
in 126 128 742 744 O
a 129 130 745 746 O
clinical 131 139 747 755 O
trial 140 145 756 761 O
involving 146 155 762 771 O
an 156 158 772 774 O
investigational 159 174 775 790 O
product 175 182 791 798 O
or 183 185 799 801 O
any 186 189 802 805 O
other 190 195 806 811 O
type 196 200 812 816 O
of 201 203 817 819 O
medical 204 211 820 827 O
research 212 220 828 836 O
judged 221 227 837 843 O
not 228 231 844 847 O
to 232 234 848 850 O
be 235 237 851 853 O
scientifically 238 252 854 868 O
or 253 255 869 871 O
medically 256 265 872 881 O
compatible 266 276 882 892 O
with 277 281 893 897 O
this 282 286 898 902 O
study 287 292 903 908 O

Have 0 4 909 913 O
prior 5 10 914 919 B-cancer
malignancies 11 23 920 932 I-cancer
. 23 24 932 933 O
Participants 25 37 934 946 O
with 38 42 947 951 O
carcinoma 43 52 952 961 B-cancer
in 53 55 962 964 I-cancer
situ 56 60 965 969 I-cancer
of 61 63 970 972 O
any 64 67 973 976 O
origin 68 74 977 983 O
and 75 78 984 987 O
participants 79 91 988 1000 O
with 92 96 1001 1005 O
prior 97 102 1006 1011 O
malignancies 103 115 1012 1024 O
who 116 119 1025 1028 O
are 120 123 1029 1032 O
in 124 126 1033 1035 O
remission 127 136 1036 1045 O
and 137 140 1046 1049 O
whose 141 146 1050 1055 O
likelihood 147 157 1056 1066 O
of 158 160 1067 1069 O
recurrence 161 171 1070 1080 O
is 172 174 1081 1083 O
very 175 179 1084 1088 O
low 180 183 1089 1092 O
, 183 184 1092 1093 O
as 185 187 1094 1096 O
judged 188 194 1097 1103 O
by 195 197 1104 1106 O
the 198 201 1107 1110 O
Lilly 202 207 1111 1116 O
clinical 208 216 1117 1125 O
research 217 225 1126 1134 O
physician 226 235 1135 1144 O
, 235 236 1144 1145 O
are 237 240 1146 1149 O
eligible 241 249 1150 1158 O
for 250 253 1159 1162 O
this 254 258 1163 1167 O
study 259 264 1168 1173 O

Have 0 4 1174 1178 O
symptomatic 5 16 1179 1190 B-cancer
central 17 24 1191 1198 I-cancer
nervous 25 32 1199 1206 I-cancer
system 33 39 1207 1213 I-cancer
malignancy 40 50 1214 1224 I-cancer
or 51 53 1225 1227 O
metastasis 54 64 1228 1238 O

Part 0 4 1239 1243 O
C 5 6 1244 1245 O
: 6 7 1245 1246 O
Advanced 8 16 1247 1255 O
, 16 17 1255 1256 O
unresectable 18 30 1257 1269 O
cancer 31 37 1270 1276 B-cancer
( 38 39 1277 1278 O
dose 39 43 1278 1282 O
escalation 44 54 1283 1293 O
) 54 55 1293 1294 O
and 56 59 1295 1298 O
advanced 60 68 1299 1307 O
, 68 69 1307 1308 O
unresectable 70 82 1309 1321 O
, 82 83 1321 1322 O
or 84 86 1323 1325 O
metastatic 87 97 1326 1336 B-cancer
non 98 101 1337 1340 I-cancer
- 101 102 1340 1341 I-cancer
small 102 107 1341 1346 I-cancer
cell 108 112 1347 1351 I-cancer
lung 113 117 1352 1356 I-cancer
cancer 118 124 1357 1363 I-cancer
with 125 129 1364 1368 O
a 130 131 1369 1370 O
BRAF 132 136 1371 1375 O
or 137 139 1376 1378 O
RAS 140 143 1379 1382 O
mutation 144 152 1383 1391 O
, 152 153 1391 1392 O
and 154 157 1393 1396 O
colorectal 158 168 1397 1407 B-cancer
cancer 169 175 1408 1414 I-cancer
with 176 180 1415 1419 O
a 181 182 1420 1421 O
RAS 183 186 1422 1425 O
mutation 187 195 1426 1434 O
and 196 199 1435 1438 O
advanced 200 208 1439 1447 O
or 209 211 1448 1450 O
metastatic 212 222 1451 1461 B-cancer
cancer 223 229 1462 1468 I-cancer
with 230 234 1469 1473 O
an 235 237 1474 1476 O
activating 238 248 1477 1487 O
mitogen 249 256 1488 1495 O
activated 257 266 1496 1505 O
protein 267 274 1506 1513 O
kinase 275 281 1514 1520 O
pathway 282 289 1521 1528 O
alteration 290 300 1529 1539 O
( 301 302 1540 1541 O
dose 302 306 1541 1545 O
expansion 307 316 1546 1555 O
) 316 317 1555 1556 O

Part 0 4 1557 1561 O
D 5 6 1562 1563 O
: 6 7 1563 1564 O
Have 8 12 1565 1569 O
metastatic 13 23 1570 1580 B-cancer
pancreatic 24 34 1581 1591 B-cancer
ductal 35 41 1592 1598 I-cancer
adenocarcinoma 42 56 1599 1613 I-cancer
( 57 58 1614 1615 O
dose 58 62 1615 1619 O
escalation 63 73 1620 1630 O
and 74 77 1631 1634 O
dose 78 82 1635 1639 O
expansion 83 92 1640 1649 O
) 92 93 1649 1650 O

planning 0 8 1651 1659 B-pregnancy
to 9 11 1660 1662 I-pregnancy
become 12 18 1663 1669 I-pregnancy
pregnant 19 27 1670 1678 I-pregnancy

pregnant 0 8 1679 1687 B-pregnancy

